Search
Stanford professor James Zou and his team created a virtual lab with AI scientists - they designed nanobodies for a COVID variant
Dr. Zou describes this work, which was published recently in Nature, and how the the AI scientists were able to do everything from debate...
Aug 26
MassBio's CEO Kendalle Burlin O'Connell shares the details of today's just published 2025 Industry Snapshot - a key barometer of the health of biotech not just in Massachusetts, but as an industry
She discusses the report and specifics on NIH funding, VC investment, jobs, biotech clusters within Massachusetts, and more. VIEW THE...
Aug 26
William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron
He shares his take on today's data, which saw Viking's stock decline by over 40%, and Lilly's earlier data which also sparked a Wall...
Aug 19
Biotech CEO Sisterhood: Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership
Interviewed by Xilio Therapeutics President & CEO René Russo, Dr. Liebisch describes her start in the industry as a patent attorney,...
Aug 19
Celebrating the 2025 Nucleate Alumni Summit
Nucleate leaders describe what Nucleate has done for their education and career, and what they are looking forward to at this year's...
Aug 18
After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires
Founder & CEO Ashoka Rejendra describes what the company offers, which is a not only a software package, but guidance on how to build and...
Aug 18
Two experts in genetic medicines, Devan Shah and Michelle Lynn Hall, discuss the recently announced federal funding cuts for mRNA research and what it means for this area of science going forward
They explain the size and depth of the cuts, and how it will affect research on both respiratory and non-respiratory conditions. Plus,...
Aug 17
Biotech Direct: MassBio CEO Kendalle Burlin O'Connell and Seaport Therapeutics Founder & CEO Daphne Zohar discuss NIH funding, recent developments at FDA, and improving the public's view of science
In this inaugural episode of Biotech Direct, BiotechTV's new show that will share the biotech industry's perspective on policy and...
Aug 15
IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead
Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly...
Aug 15
Visiting Genezen Indianpolis to see where it all started - and where the company today makes lenti and retroviral vectors for cell and gene therapies
BiotechTV visited our sponsor Genezen's Indianapolis facility last week where they manufacture lenti and retroviral vectors for gene and...
Aug 13
Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced...
Aug 13
Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis
Co-Founder & CEO Jim Martineau walks us through the platform and describes the importance of being cell type specific. The company...
Aug 13
Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and...
Aug 12
IDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year
Founder & CEO Yujiro Hata describes the idea behind precision medicine and synthetic lethality. We discuss the company's pipeline assets...
Aug 12
CytomX Therapeutics' years of work on its 'Probody' masking technology may be paying off at a time when there is growing focus on this approach - it presented key initial data on its EpCAM ADC in May
Chairman & CEO Sean McCarthy walks us through the science and describes what CytomX has learned about it over many years of working on...
Aug 11
Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease
CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the...
Aug 11
BioVenture VoiCes Episode 24: Samsara Biocapital's Srini Akkaraju
The Founder & Managing Partner of Samsara Biocapital, Dr. Akkaraju describes his early move from Standford to industry and various...
Aug 10
Astria Therapeutics licensed its HAE treatment, Navenibart, to Kaken Pharmaceutical for the Japanese market. It is a kallikrein inhibitor that is in phase 3, and is dosed up to every six months
President and CEO Jill Milne describes what she believes is the unmet need and profile of Navenibart, and walks us through future...
Aug 7
AI News: While most AI in healthcare is aimed at helping physicians better diagnose and treat disease, CureWise is built for patients to help understand their conditions and ask the right questions
Founder & CEO Steve Brown, who created CureWise after receiving his own diagnosis of a rare blood cancer, describes his journey and how...
Aug 7
Biotech CEO Sisterhood: Trevi Therapeutics' Co-Founder & CEO Jennifer Good on effective communication and capital efficiency, and a unique internship program in life sciences
Interviewed by Sisterhood editorial board member Erika Smith, Jennifer Good describes the factors that have led to Trevi's success in an...
Aug 6
.png){kind=logo}
